Sepideh Gholami, MD
Surgical Oncology · Sacramento, CANPI 1982865606
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Boston Scientific at 30.1% of the total. Among surgical oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 58 payments — averaging $544.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- Helsinn Therapeutics (U.S.), Inc.$9K
- Intuitive Surgical$4K
- Genentech USA, Inc.$4K
- Delcath Systems$2K
- Histosonics, Inc.$1K
- plus $2K from 8 others
Across 11 payments — averaging $18,684 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$126K
- Amgen$79K
What the payments were for
- Consulting fees$10,16532%
- Speaking & faculty fees$11,55637%
- Travel & lodging$3,35211%
- Food & beverage$3,51911%
- Education$3,0009%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $9,523 |
| Helsinn Therapeutics (U.S.), Inc. | 4 | $8,543 |
| Intuitive Surgical | 10 | $4,154 |
| Genentech USA, Inc. | 7 | $4,114 |
| Delcath Systems | 1 | $1,800 |
| Histosonics, Inc. | 2 | $1,338 |
| Dilon Technologies, Inc. | 17 | $992 |
| Intera Oncology, Inc | 3 | $673 |
| Trisalus Life Sciences, Inc. | 1 | $123 |
| Conmed Corporation | 1 | $121 |
| Genentech, Inc. | 1 | $70 |
| Medtronic | 1 | $53 |
| E.r. Squibb & Sons, L.L.C. | 1 | $51 |
| Solventum Corporation | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRUSELTIQ$8,450
- General - Interventional Oncology$8,306
- TECENTRIQ$3,946
- Da Vinci Surgical System$3,803
- Hepzato Kit$1,800
- TheraSphere Y90 Glass Microspheres 10 GBq$1,042
- HemoBlast Bellows$567
- Intera 3000 Implantable Pump$552
- TRINAV INFUSION SYSTEM$123
- AIRSEAL$121
- INTERA$121
How this compares
$31,592 in reported general payments places this provider in the 90th percentile of 209 surgical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Sacramento
- Smit SinglaSacramento$11K
- Afshin BahadorSan Diego$701K
- Amir FathiFresno$255K
- Alexander ChristSanta Monica$239K
- Yanghee WooDuarte$131K
- Michael BouvetSan Diego$118K
- Yuman FongDuarte$87K
- Ronald HurstLos Angeles$76K
- Jason Sicklickla Jolla$69K
- Mohammed Al-TemimiSan Jose$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.